SNX8: Sorting Nexin 8 – A Key Regulator of Endosomal Trafficking and Signaling

Comprehensive genomic, proteomic, and clinical overview of SNX8, a member of the sorting nexin family involved in intracellular membrane trafficking and implicated in neurodegenerative and metabolic disorders.

Gene Information Card

Symbol SNX8
Full Name Sorting Nexin 8
Gene Type Protein coding
Chromosomal Location 2p25.1
NCBI Gene ID 29886 ncbi.nlm.nih.gov/gene/29886
Ensembl ID ENSG00000162928
UniProt ID Q9Y2X7
OMIM ID 611349
HGNC ID 11173
Aliases SNX8, MGC138290, MGC138291

Description

SNX8 (sorting nexin 8) encodes a member of the sorting nexin family, characterized by a Phox (PX) domain that binds phosphoinositides. SNX8 is involved in endosomal trafficking, retromer complex function, and regulation of cell surface receptor recycling. It plays roles in intracellular signaling, lipid metabolism, and autophagy. Variants in SNX8 have been associated with Alzheimer disease, type 2 diabetes, and other metabolic traits.

Disease Associations

Disease category Pathophysiological mechanism Genomic evidence
Alzheimer disease SNX8 modulates retromer-mediated trafficking of APP and BACE1, affecting amyloid-beta production; loss of SNX8 impairs endosomal sorting and promotes Aβ accumulation. ClinVar, OMIM
Type 2 diabetes SNX8 variants influence insulin receptor recycling and GLUT4 translocation, altering glucose uptake and insulin sensitivity. GWAS, NCBI
Obesity SNX8 expression in adipose tissue correlates with lipid metabolism; variants linked to body mass index. GWAS, ClinVar

Expression Profile

Tissue Expression
Tissue nTPM level
Brain (cortex) 12.5 Medium
Liver 8.3 Low
Adipose tissue 6.1 Low
Pancreas 4.7 Low
Skeletal muscle 3.2 Not detected
Cell Line Expression
Cell Line nTPM Notes
SH-SY5Y (neuroblastoma) 15.2 High expression; used in neurodegeneration studies
HepG2 (hepatocellular carcinoma) 9.8 Moderate expression
3T3-L1 (adipocyte) 7.4 Differentiation-dependent expression
HeLa (cervical carcinoma) 5.1 Low expression
Data source:Human Protein Atlas(proteinatlas.org)

Mutations & Variants

Hotspot Mutations
Variant Type Frequency Functional Description
c.497C>T (p.Thr166Met) Missense 0.0012 (gnomAD) Alters PX domain; reduced phosphoinositide binding; associated with Alzheimer disease risk
c.1045G>A (p.Gly349Arg) Missense 0.0008 Impairs retromer interaction; linked to type 2 diabetes
c.1234_1235insA Frameshift <0.0001 Loss of function; rare; observed in metabolic syndrome
Mutation functional classification

Loss of Function (LOF)

Frameshift and nonsense mutations that truncate the protein or disrupt the PX domain lead to loss of endosomal trafficking function.

Gain of Function (GOF)

No confirmed gain-of-function mutations reported in SNX8.

Dominant Negative (DN)

Missense mutations in the PX domain (e.g., p.Thr166Met) may exert dominant-negative effects by competing with wild-type SNX8 for phosphoinositide binding.

Pathways

• Retromer-mediated endosomal sorting (Reactome: R-HSA-8856828)
• Endosomal trafficking (KEGG: hsa04144)
• Alzheimer disease – amyloid processing (KEGG: hsa05010)
• Insulin receptor recycling (WikiPathways: WP481)

Protein Summary

SNX8 is a 465-amino-acid protein containing an N-terminal Phox (PX) domain that binds phosphatidylinositol 3-phosphate (PI3P) and phosphatidylinositol 3,5-bisphosphate (PI(3,5)P2). It localizes to early endosomes and participates in retromer-dependent retrograde transport from endosomes to the Golgi. SNX8 also interacts with the retromer subunit VPS35 and regulates the trafficking of APP, BACE1, and the insulin receptor. Its expression is enriched in brain and adipose tissue, and it is implicated in Alzheimer disease and metabolic disorders.

Related Products

Product name Cat.No. Species Gene ID
SNX8 Knockout HEK293 Cell Line EDJ-KQ8305 Human 29886 Details Get a Quote
SNX8 Knockout A-549 Cell Line EDJ-KQ35525 Human 29886 Details Get a Quote
SNX8 Knockout HCT 116 Cell Line EDJ-KQ35527 Human 29886 Details Get a Quote
SNX8 Knockout HeLa Cell Line EDJ-KQ35528 Human 29886 Details Get a Quote
Contact Us
*
*
*
How did you hear about us: